Compare SKYH & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYH | PALI |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | 112 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 321.0M | 359.7M |
| IPO Year | N/A | 2019 |
| Metric | SKYH | PALI |
|---|---|---|
| Price | $9.18 | $1.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $13.13 | $11.29 |
| AVG Volume (30 Days) | 175.4K | ★ 2.5M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 97.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $260,000.00 |
| Revenue This Year | $78.89 | N/A |
| Revenue Next Year | $73.15 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $8.22 | $0.55 |
| 52 Week High | $11.17 | $2.86 |
| Indicator | SKYH | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 45.57 | 44.36 |
| Support Level | $9.08 | $1.78 |
| Resistance Level | $9.53 | $2.12 |
| Average True Range (ATR) | 0.32 | 0.14 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 46.98 | 30.10 |
Sky Harbour Group Corp is an aviation infrastructure company focused on building the first nationwide network of Home Base Operator (HBO) campuses designed exclusively for business aircraft. The company develops, leases, and manages general aviation hangars across the United States, targeting airfields in markets with aircraft populations and high hangar demand. Its HBS campuses include private hangars and offer a range of services tailored to aircraft owners operating from these facilities. The majority of the company's revenue is derived from the leasing of home-based aircraft hangars and through services and products ancillary to its leasing activities.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.